CancerPATROLNCT07256444
Feasibility Study of a Transition Pathway at Discharge From Full Hospitalization in Oncology
An observational study of Cancer, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
Trial summary
Patient reported outcomes (PRO) measure the health status directly reported by the patients, without external interpretation, generally collected using self-questionnaires, including online tools (ePRO). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- OncoCare transition program
- How many people
- 50 participants
- Where
- 1 siteFrance
- Study dates
- 2 Jun 2026to Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Consecutive patients treated as inpatients in the Medical Oncology Department of Nîmes University Hospital and scheduled to be discharged and returned home.
Who may be able to join
- The patient must have given their free and informed consent and signed the consent form
- The patient must be a member or beneficiary of a health insurance plan
- Adult patient hospitalized in an oncology unit for at least 48 hours.
- Patient capable of using a connected device, in possession of a smartphone or tablet, and with an internet connection at home.
- Patient discharged from hospital to go home.
Who cannot join
- The patient is in a period of exclusion determined by a previous study
- The subject refuses to sign the consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Patient considered to be at the end of life.
- Patient unable to read and understand French
Show all 9Show fewer
- Patient discharged from hospitalization to a home care facility
- Patient having been hospitalized in a full-time inpatient setting for a scheduled procedure (chemotherapy or interventional procedure)
- Pregnant, parturient, or breastfeeding
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Centre Hospitalier de Nimes
Nîmes, 30000
Anissa Megzari, Doctor, 04.66.68.42.36, drc@chu-nimes.fr
Astrid Basset
About this study
Official title: Etude de faisabilité d'un Parcours de Transition à la Sortie d'Hospitalisation complète en Oncologie - Etude Pilote Monocentrique
Patient reported outcomes (PRO) measure the health status directly reported by the patients, without external interpretation, generally collected using self-questionnaires, including online tools (ePRO). This approach is useful in early detection of signs of relapse, with reduced anxiety, improved quality of life and survival, and reduced readmissions to emergency departments in patients with advanced cancer. In the current context where hospitalization is increasingly short, the transition from hospital to home is a critical moment that poses a significant safety challenge Patient follow-up strategies help patients return home, particularly in surgery, with telephone calls from a nurse the day after or several days after discharge. In oncology, telephone calls from the pharmacist 3 days after discharge from hospital helped to identify undesirable effects of treatments. In general medicine, these calls have led to improved patient satisfaction, reduced use of emergency departments and the resolution of drug-related problems, but are costly. The introduction of post-hospitalization ePRO monitoring in oncology could ensure effective follow-up while keeping costs under control. A coordinating nurse could manage this process and play a crucial role in accompanying patients when they return home.
The study authors aimed to evaluate the feasibility of a transitional nurse consultation and ePRO follow-up on discharge from full hospitalization in oncology in this population of frail and elderly patients.
- Conditions
- Cancer
- Being tested
- OncoCare transition program
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OncoCare transition programOther
Interview with the coordinating nurse who reviews the patient's prescriptions and appointments, installs the electronic patient-reported outcome (ePRO) application on the patient's smartphone and explains collection of any symptoms.
ePRO symptom monitoring by the patient on D2, D7 and D15 after discharge. The coordinating nurse phones the patient on D7 to review the symptoms reported, assess compliance with treatment and provide support. In the event of grade ≥ 2 symptoms, the nurse contacts the patient for further information and informs the referring oncologist, who decides on the course of treatment.
What is being measured
The primary outcome is the main question the study is designed to answer.
Compliance with ePRO monitoring
Percentage of patients who responded to all questionnaires
Measured: Day 2
Compliance with the telephone call at day 7
Percentage of patients successfully contacted at day 7
Measured: Day 7
Patient satisfaction with the care pathway
Question: "Are you satisfied with your care pathway?" (Yes/no)
Measured: Day 15
Secondary outcomes (7)
Quality of the transition pathway to home
Care Transitions Measure (CTM-3) questionnaire, where a 10-point increase reduces the risk of readmission by 14%
Measured: Day 15
Quality of life as reported by the patient
EORTC QLQ-C30 questionnaire: The score for each subscale ranges from 0 to 100and good quality of life is associated with a high score on the functional scales and a low score on the symptom scales.
Measured: Day 0
Quality of life as reported by the patient
EORTC QLQ-C30 questionnaire: The score for each subscale ranges from 0 to 100and good quality of life is associated with a high score on the functional scales and a low score on the symptom scales.
Measured: Day 7
Quality of life as reported by the patient
EORTC QLQ-C30 questionnaire: The score for each subscale ranges from 0 to 100and good quality of life is associated with a high score on the functional scales and a low score on the symptom scales.
Measured: Day 15
Quality of life as reported by the patient
EORTC QLQ-C30 questionnaire: The score for each subscale ranges from 0 to 100and good quality of life is associated with a high score on the functional scales and a low score on the symptom scales.
Measured: Day 30
Patient satisfaction with their care
EORTC PATSAT-C33 questionnaire: The total score ranges from 0 to 100
Measured: Day 15
Rate of readmissions to a healthcare facility
Rate of readmissions to healthcare establishments (hospitalization department, emergency room)
Measured: One month after hospitalization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2025
- Study start2 Jun 2026
- Primary completionDec 2028 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NīmesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Astrid Basset, Principal investigator, CHU de Nimes
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07256444
- Sponsor's protocol ID
- NIMAO/2023-2/AB01
- Acronym
- PATROL
- Status last verified
- Jun 2026
- First submitted
- 20 Nov 2025
- Last updated
- 9 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Etude de faisabilité d'un Parcours de Transition à la Sortie d'Hospitalisation complète en Oncologie - Etude Pilote Monocentrique
- ClinicalTrials.gov ID
- NCT07256444
- Acronym / sponsor ID
- PATROL / NIMAO/2023-2/AB01
- Conditions
- Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire de NīmesUniversity, hospital or other
- Study start
- 2 Jun 2026 (actual)
- Primary completion
- Dec 2028 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 1 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patient reported outcomes (PRO) measure the health status directly reported by the patients, without external interpretation, generally collected using self-questionnaires, including online tools (ePRO). This approach is useful in early detection of signs of relapse, with reduced anxiety, improved quality of life and survival, and reduced readmissions to emergency departments in patients with advanced cancer. In the current context where hospitalization is increasingly short, the transition from hospital to home is a critical moment that poses a significant safety challenge Patient follow-up strategies help patients return home, particularly in surgery, with telephone calls from a nurse the day after or several days after discharge. In oncology, telephone calls from the pharmacist 3 days after discharge from hospital helped to identify undesirable effects of treatments. In general medicine, these calls have led to improved patient satisfaction, reduced use of emergency departments and the resolution of drug-related problems, but are costly. The introduction of post-hospitalization ePRO monitoring in oncology could ensure effective follow-up while keeping costs under control. A coordinating nurse could manage this process and play a crucial role in accompanying patients when they return home.
The study authors aimed to evaluate the feasibility of a transitional nurse consultation and ePRO follow-up on discharge from full hospitalization in oncology in this population of frail and elderly patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Consecutive patients treated as inpatients in the Medical Oncology Department of Nîmes University Hospital and scheduled to be discharged and returned home.
Key inclusion criteria (5 listed)
- The patient must have given their free and informed consent and signed the consent form
- The patient must be a member or beneficiary of a health insurance plan
- Adult patient hospitalized in an oncology unit for at least 48 hours.
- Patient capable of using a connected device, in possession of a smartphone or tablet, and with an internet connection at home.
- Patient discharged from hospital to go home.
Key exclusion criteria (9 listed)
- The patient is in a period of exclusion determined by a previous study
- The subject refuses to sign the consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Patient considered to be at the end of life.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OncoCare transition programInterview with the coordinating nurse who reviews the patient's prescriptions and appointments, installs the electronic patient-reported outcome (ePRO) application on the patient's smartphone and explains collection of any symptoms. ePRO symptom monitoring by the patient on D2, D7 and D15 after discharge. The coordinating nurse phones the patient on D7 to review the symptoms reported, assess compliance with treatment and provide support. In the event of grade ≥ 2 symptoms, the nurse contacts the patient for further information and informs the referring oncologist, who decides on the course of treatment. | Other | – |
Primary outcome
Compliance with ePRO monitoring
Time frame: Day 2
Percentage of patients who responded to all questionnaires
Compliance with the telephone call at day 7
Time frame: Day 7
Percentage of patients successfully contacted at day 7
Patient satisfaction with the care pathway
Time frame: Day 15
Question: "Are you satisfied with your care pathway?" (Yes/no)
7 secondary outcomes
Quality of the transition pathway to home
Time frame: Day 15
Quality of life as reported by the patient
Time frame: Day 0
Quality of life as reported by the patient
Time frame: Day 7
Quality of life as reported by the patient
Time frame: Day 15
Quality of life as reported by the patient
Time frame: Day 30
Patient satisfaction with their care
Time frame: Day 15
Rate of readmissions to a healthcare facility
Time frame: One month after hospitalization
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jun 2026.
Related trials for Cancer
Not yet recruiting
Using e-Technologies to Maximize Physical Activity After Cancer Treatment
Cancer
RecruitingPhase 1
IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies
RecruitingObservational study
Pharmacogenetic Determinants Of Treatment Response In Children
All Malignancies, Children Being Treated for Catastrophic Illness
RecruitingObservational study
Cancer in Inherited Bone Marrow Failure Syndromes
Diamond Blackfan Anemia, Dyskeratosis Congenita
RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Astrid Basset principal investigator
CHU de Nimes
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Astrid Basset (06.24.89.63.27, astrid.basset@chu-nimes.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compliance with ePRO monitoring (time frame: Day 2). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2026.